Business
Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy
Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 /Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases ...
About this update from Lobe Sciences Ltd
[{"type":"text","content":"Balance Sheet and Sharpened Strategy","length":36,"tagName":"p"},{"type":"text","content":"VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported audited financial results for the fiscal year ended August 31, 2025 ("FY2025") and provided an update on operational progress achieved since the Company's leadership transition and Board renewal beginning in late 2024.","length":506,"tagName":"p"},{"type":"text","content":"Dr. Frederick D. Sancilio, Chairman and CEO of Lobe Sciences, stated: "Fiscal 2025 was about strengthening Lobe's balance sheet and funding our core assets responsibly. Advancing L-130 through Cynaptec Pharmaceuticals, Inc. allowed us to secure development capital while limiting dilution at Lobe, which we believe better aligns capital with asset value."","length":369,"tagName":"p"},{"type":"text","content":"Financial Highlights: FY2025","length":28,"tagName":"p"},{"type":"text","content":"In FY2025, Lobe improved its balance sheet position and liquidity profile:","length":74,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cash increased to $5,854,118 on August 31, 2025, compared to $237,772 on August 31, 2024","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Working capital improved to a surplus of $5,163,526, compared to a deficit of $2,008,849 on August 31, 2024","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"The current portion of the convertible notes were eliminated on August 31, 2025, as compared to $641,374 on August 31, 2024","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"Derivative liability decreased to $205,105 on August 31, 2025, from $603,724 on August 31, 2024","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Short-term investments of $1,686,688 were held on August 31, 2025 (none reported on August 31, 2024)","length":100,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":513,"olType":false},{"type":"text","content":"Loss per share was $0.03 for fiscal 2025, compared to $0.04 for fiscal 2024, despite significant balance-sheet restructuring and increased investment ...